Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Dr. Mark Yarchoan is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018. Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies. He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research. Dr. Yarchoan is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.

Jin He, M.D., Ph.D., is a professor of surgery at the Johns Hopkins University School of Medicine and is the Division Chief of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology. Dr. He specializes in diseases and tumors of the pancreas, liver, bile duct, and gallbladder. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure. Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by an ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins. Dr. He is the John Cameron Professor of Alimentary Tract Diseases. Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees, including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology. Dr. He is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Marina Baretti, MD, is an assistant professor at Johns Hopkins University School of Medicine and the Jiasheng Chair in Hepato-Biliary Cancer Research. She also serves as Co-Director of the Liver and Biliary Cancer Multidisciplinary Clinic at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Dr. Baretti received her medical degree from the University of Pisa in Italy. She completed her internal medicine residency and oncology fellowship at University of Milan. She then went on and completed her Postdoctoral and Medical Oncology Fellowship at Johns Hopkins University, Baltimore, Maryland. She is deeply engaged in bridging the gap between laboratory discoveries and clinical application, working closely with laboratory-based scientists to accelerate the development of novel therapeutic strategies. Her academic research is centered on the development of novel agents in hepatobiliary cancers, with particular interest in combinatorial approaches of immunotherapies. She is currently the principal investigator on multiple clinical trials in FLC, HCC and cholangiocarcinoma at Johns Hopkins University, collaborating closely with laboratory-based researchers to move laboratory findings into patients. Through her work, Dr. Baretti strives to improve outcomes for patients with rare GI cancers by identifying innovative therapies that are informed by a deeper understanding of tumor biology and the tumor microenvironment. Dr. Baretti was the recipient of the 2018 American Society of Clinical Oncology Young Investigator Award. Dr. Baretti was also awarded with the 2020 Career Development Award for the MD Anderson Cancer Center’s pancreatic cancer NCI Specialized Programs of Research Excellence (SPORE). Dr. Baretti is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, and Pancreatic Cancer.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Kelly Lafaro, MD, MPH, is a general surgeon with a specialty in gastrointestinal surgical oncology and hepatobiliary surgery. She is part of the Johns Hopkins Kimmel Cancer Center. Dr. Lafaro earned her medical degree from Tulane University School of Medicine and completed her residency at New York-Presbyterian/Columbia University Irving Medical Center. Her fellowship in complex general surgical oncology was completed at City of Hope National Medical Center. Dr. Lafaro’s expertise includes pancreatic adenocarcinoma, neuroendocrine tumors, minimally invasive pancreatic and liver surgeries, and colorectal liver metastases. In addition to her clinical experience, Dr. Lafaro is published in the field of liver and pancreatic cancer. She is interested in the improvement of surgical and post-surgical outcomes. Dr. Lafaro is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreatectomy, and Pancreaticoduodenectomy.

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Gastroenterologist Mouen Khashab specializes in therapeutic endoscopy, and he oversees this group of practitioners across the Johns Hopkins enterprise. Nationally and internationally known in the field of interventional endoscopy, Dr. Khashab has contributed immensely to the field’s advancement as a minimally invasive means to treat gastrointestinal and pancreaticobiliary disorders. Dr. Khashab earned his medical degree from the American University of Beirut Faculty of Medicine, and subsequently completed a residency in internal medicine and a fellowship in gastroenterology at Indiana University. He then completed a two-year fellowship at The Johns Hopkins Hospital before joining the faculty in 2011. A busy researcher, Dr. Khashab has published more than 600 papers in peer-reviewed journals. In 2013, he described the procedure called gastric peroral endoscopic myotomy (known as G-POEM) and was able to disseminate and teach it all over the world. Other procedures that he expanded include peroral endoscopic myotomy (POEM), peroral endoscopic myotomy with fundoplication (POEM-F), Zenker’s peroral endoscopic myotomy (Z-POEM) and full thickness resection. In 2022, he received the Master Endoscopist Award from the American Society for Gastrointestinal Endoscopy (ASGE) for his numerous contributions to the field. His procedural expertise includes endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), interventional EUS, submucosal endoscopy, POEM/achalasia, endoscopic mucosal resection, endoscopic submucosal dissection, luminal stenting, large polyp resection and Barrett’s therapy, among others. Dr. Khashab is involved with multiple gastrointestinal societies and has served on many committees, including the ASGE Standards of Practice Committee, which is in charge of formulating guidelines for the practice of endoscopy. He has also served as an associate editor for the journal Endoscopy, a premier journal in the field. Khashab is a highly sought-after speaker at national and international conferences, and he has participated in multiple live endoscopy conferences. Outside of academic medicine, Dr. Khashab is an entrepreneur. His major interest is in new technology and medical devices, and his goal is to disrupt the field by introducing technology that makes endoscopic procedures safer, easier, efficient and more scalable. Dr. Khashab is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Achalasia, Pancreatic Pseudocyst, Bile Duct Obstruction, Endoscopy, and Gastric Bypass.

Dr. Brian Holly is an assistant professor of radiology and radiological science. Dr. Holly's clinical focus lies in venous thromboembolic disease. He specializes in the diagnosis and treatment of deep venous thrombosis, pulmonary embolism, post thrombotic syndrome; advanced venous interventions including prostatic artery embolization (PAE); IVC filter removal; treatment of vascular malformations; treatment of uterine fibroids and advanced biliary interventions. Dr. Holly received his M.D. from the University of Maryland School of Medicine in 2007. He completed an internship in internal medicine at Mercy Medical Center in 2008. He completed residency in radiology in 2012 at the University of Maryland Medical Center. This was followed by a fellowship in vascular and interventional radiology in 2013 at The Johns Hopkins Hospital. He is a member of the Society of Interventional Radiology. Recent News Articles and Media Coverage Minimally Invasive Treatment for Uterine Fibroids Webinar Uterine fibroids are non-cancerous growths that develop from the muscle tissue of the uterus. Interventional radiologist, Brian Holly, M.D., and gynecologist, Khara Simpson, M.D., hosted this interactive webinar to discuss a non-surgical alternative for uterine fibroids called uterine fibroid embolization. Dr. Holly is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Deep Vein Thrombosis, Enlarged Prostate (BPH), Cholangiocarcinoma (Bile Duct Cancer), Gastrostomy, and Liver Embolization.

Gastroenterologist Florin Selaru has faculty appointments to the Division of Gastroenterology and Hepatology; the Johns Hopkins Kimmel Cancer Center; and the Department of Biomedical Engineering and the Institute of NanoBioTechnology at The Johns Hopkins University. He is a clinical expert in inflammatory bowel disease (IBD) and serves as the director of the Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center at Johns Hopkins. Dr. Selaru earned his medical degree at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. He completed his internal medicine residency at University of Maryland Medical Center in Baltimore and completed his fellowship training in gastroenterology and hepatology at the Johns Hopkins University School of Medicine. Dr. Selaru’s research focuses on the intersection of clinical medicine, engineering and biology. His research expertise is in the utilization of bioengineering tools to answer clinically relevant questions and to translate findings for use in the clinical setting. He established and leads the Selaru lab, a National Institutes of Health-funded laboratory at Johns Hopkins that focuses on inflammation, fibrosis and cancer. The Selaru lab specializes in drug and device development for inflammatory and malignant conditions, as well as tissue regeneration solutions. Some specific projects include drug development for fibrosis in the gastrointestinal tract, microrobot development for oral drug delivery, tissue engineering for fistulas and other tissue defects in IBD, and novel drug targeting approaches for inflammation and cancer. Dr. Selaru’s overarching goal is to deliver medical products and technologies to patients with IBD and cancer. Dr. Selaru is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Viral Gastroenteritis, Cholangiocarcinoma (Bile Duct Cancer), Crohn's Disease, Gastrointestinal Fistula, and Endoscopy.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Dr. Robert Liddell is an Assistant Professor of Radiology and Surgery and Division Chief of Interventional Radiology at the Johns Hopkins School of Medicine. His specialty is interventional radiology, with an expertise in interventional oncology and vascular and interventional radiology. Dr. Liddell received his MBBCh at the Royal College of Surgeons in Ireland. He completed his residency at Johns Hopkins University School of Medicine in Diagnostic Radiology and his fellowship in Interventional Radiology. Videos Interventional Radiology. Dr. Liddell is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Bile Duct Obstruction, Ascites, Fibrolamellar Carcinoma, Liver Embolization, and Pancreaticoduodenectomy.

Dr. Satomi Kawamoto is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. She specializes in computed tomography (CT), ultrasound, and image-guided biopsy. Dr. Kawamoto received her M.D. from Gunma University in Gunma, Japan, and subsequently completed two residencies, one in internal medicine at St. Luke’s International Hospital in Tokyo, and a second in diagnostic radiology at Johns Hopkins. She received a postdoctoral fellowship in cross-sectional imaging at Johns Hopkins, and then joined the Johns Hopkins faculty. Dr. Kawamoto’s research focuses on body CT and biopsy, particularly imaging of the genitourinary and gastrointestinal systems. Dr. Kawamoto is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Neuroendocrine Tumor, Muscle Invasive Bladder Cancer, Cavernous Lymphangioma, Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

Dr. Elliot K. Fishman is a Professor in the Johns Hopkins Medicine Department Radiology and Radiological Science, Department of Oncology and Department of Surgery. He serves as a member of the Johns Hopkins Kimmel Cancer Center. His clinical and research interests focus on medical imaging with specific emphasis on three-dimensional (3D) imaging and computed tomography (CT). Dr. Fishman received his B.S. in 1973 and M.D. in 1977 from the University of Maryland. After a residency at Sinai Hospital in Baltimore, he completed a fellowship in CT at Johns Hopkins in 1980 and joined the Johns Hopkins faculty in 1981 as an Assistant Professor. In 1986, he became Associate Professor and, in 1991, Professor of Radiology and Oncology. He is a leader in the development of 3D imaging and rendering, including its impacts on and uses in patient care and management. He was involved from the beginning in the development of 3D imaging through his work with Pixar, which was a spin-off from LucasFilms in San Rafael, California. Over the last 25 years, Dr. Fishman continued to help develop 3D imaging and has been a leader in the development of interactive 3D rendering. His team is consistently at the forefront of research and development of new visualization and post-processing techniques and technologies. Dr. Fishman's extensive body of work in CT has resulted in over 1,000 peer-reviewed publications, and he is the author or co-author of 10 textbooks. He is the recipient of three prestigious Aunt Minnie Awards, honoring his outstanding contributions as both an educator and researcher. In 2007, he was named by Medical Imaging Magazine as the Top Radiologist in the Nation. He is a member of editorial boards for more than 35 journals, an active member of several professional radiology associations and is a past-president of the Society of Body CT/MR. Dr. Fishman is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Cavernous Lymphangioma, Pancreaticoduodenectomy, and Pancreatectomy.

Ilene S. Browner, M.D. specializes in geriatric oncology. Dr. Browner is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Endoscopy.

Dr. Kelvin K. Hong is an Associate Professor and Executive Vice Chair of Radiology within the Johns Hopkins Department of Radiology. A specialist in interventional and vascular radiology, Dr. Hong serves as the Medical Director of the Johns Hopkins Interventional Radiology Center. Dr. Hong earned his medical degree from South Africa’s University Of Witwatersrand Medical School in Parktown. He completed a radiology residency at Parktown West’s College of Medicine/Radiology, as well as a cardiovascular/interventional radiology fellowship and diagnostic radiology residency at The Johns Hopkins Hospital. His areas of clinical expertise include bone, liver and soft-tissue tumors; chronic total occlusions; claudication; deep venous thrombosis; lung, esophageal and kidney cancer; peripheral arterial/vascular disease; renal artery/vascular disease; uterine fibroid tumors; varicocele; and vascular malformations and venous thromboembolism. Dr. Hong performs procedures that include radiofrequency ablation for lung, liver, kidney and bone lesions; transcatheter arterial chemoembolization for liver cancer; lower-extremity angioplasty and stenting; visceral angioplasty and stenting; embolization of uterine fibroid tumors; cryoablation for pain control; and percutaneous laser ablation of varicose veins. Dr. Hong served as editor for the book Percutaneous Tumor Ablation and contributed to Interventional Oncology: Principles and Practice. Dr. Hong is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Fibrolamellar Carcinoma, Bile Duct Obstruction, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.

Dr. Georgiades earned a series of degrees (BSc-Mechanical Engineering, MS & PhD-Radiological Sciences and an MD). He received a 1-year training in Internal Medicine at Harvard and subsequently, completed subspecialty training at Johns Hopkins in Diagnostic and Interventional Radiology. He has been a full time faculty at Johns Hopkins since 2003 (except for a 3 year hiatus 2012-2015 when he set up a private practice overseas). He has held various positions including fellowship director, clinical director and was a member of many Departmental and Institutional committees. He is a prolific researcher with more than 100 manuscripts, more than 100 abstracts, 28 book chapters and numerous presentations at national and international fora. Dr. Georgiades is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Fibrolamellar Carcinoma, Bile Duct Obstruction, Neuroendocrine Tumor, Liver Embolization, and Gastrostomy.

Christopher Shubert, M.D., M.H.A., is a general surgeon with specialty training and interests in hepato-pancreato-biliary (HPB) surgery. He is a member of the Division of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology at The Johns Hopkins Hospital. Dr. Shubert earned his medical degree from the University of Alabama School of Medicine and completed his general surgery residency at the Mayo Clinic in Rochester, Minnesota. He completed fellowship training in HPB surgical oncology and abdominal organ transplantation at the University of Toronto. In addition to his clinical experience, Dr. Shubert earned a Master's of Science in Healthcare Administration from the University of Alabama at Birmingham. Dr. Shubert's clinical interests include HPB surgery, resection of traditionally unresectable liver lesions, tumors involving the vena cava, and pancreas resections with vascular reconstruction. His research focus includes hepatobiliary and pancreatic malignancies, their respective treatments, perioperative management, and outcomes. Dr. Shubert is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Cameron has had a long and distinguished career in alimentary tract diseases and specifically in pancreatic cancer. He has won worldwide acclaim for mastering the Whipple procedure. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30 percent. He has worked to lower that to 1 percent to 2 percent at Johns Hopkins. He has operated on more patients with pancreatic cancer and done more Whipple resections than any other surgeon in the world. In addition to maintaining a busy practice that focuses mainly on pancreatic surgery, he has been a leader in the surgical profession, serving as president of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Southern Surgical Association, Society of Clinical Surgery, Society of Surgical Chairmen, Halsted Society and American Surgical Association. He served as chief of surgery for The Johns Hopkins Hospital for nineteen years. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958, and his medical degree from The Johns Hopkins University School of Medicine in 1962. All of his training in General and Thoracic Surgery was obtained at The Johns Hopkins Hospital. Dr. Cameron is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.